Oddity Tech (ODD) Q3 2025 earnings summary

Executive summary

• Achieved record Q3 2025 results with net revenue of $148 million, up 24% year-over-year, and exceeded guidance across all key metrics including revenue, profit, and EPS.

• Launched METHODIQ, a new telehealth dermatology brand, after four years of R&D and two acquisitions, expanding into medical-grade solutions.

• Continued robust growth in core brands Il Makiage and SpoiledChild, with international revenue up 40% year-over-year for the first nine months of 2025.

• Maintained strong cash position with $793 million in cash, cash equivalents, and investments, plus $200 million in undrawn credit facilities.

Financial highlights

• Q3 2025 net revenue reached $148 million, up 24% year-over-year, surpassing guidance.

• Gross margin for Q3 2025 was 71.6%, up 170 basis points year-over-year and above guidance.

• Adjusted EBITDA for Q3 2025 was $29 million, up 16% year-over-year and exceeding guidance.

• Adjusted diluted EPS for Q3 2025 was $0.40, up from $0.32 YoY and above guidance, excluding $9 million in share-based compensation.

• Free cash flow for the first nine months was $90 million, with $16 million in inventory outflows for METHODIQ and tariff planning.

• Cash, cash equivalents, and investments totaled $793 million as of September 30, 2025.

Outlook and guidance

• Full-year 2025 net revenue expected between $806 million and $809 million, representing 24%-25% year-over-year growth.

• Gross margin forecasted at approximately 72.5%.

• Adjusted EBITDA projected at $161-$163 million; adjusted diluted EPS at $2.10-$2.12, assuming no share buybacks.

• Q4 2025 guidance: net revenue $149–152 million (21–23% YoY growth), gross margin ~69%, adjusted EBITDA $10–12 million, adjusted diluted EPS $0.11–0.13.

• No change to medium-term algorithm of 20% revenue growth and 20% adjusted EBITDA margin.